Nuveen’s aTyr Pharma ATYR Stock Holding History

Nuveen’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-229,284	Closed	-$179K	–	3859
2026 Q1	$179K	Buy	229,284 +1,343	+0.6%	+$1.13K	﹤0.01%	3120
2025 Q4	$179K	Hold	227,941	–	–	﹤0.01%	3162
2025 Q3	$164K	Buy	227,941 +33,829	+17%	+$153K	﹤0.01%	3188
2025 Q2	$984K	Buy	+194,112	New	+$764K	﹤0.01%	2610

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's ATYR Position: Q2 2026 in Review

Nuveen sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 229,284 shares — an estimated $179K sold.

Nuveen first reported a position in ATYR in Q2 2025 and held it in 4 quarters. The position peaked at $984K in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Nuveen reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
Nuveen sold 229,284 aTyr Pharma shares in Q2 2026, an estimated $179K.
Nuveen first reported a position in aTyr Pharma in Q2 2025 and held it in 4 quarters.
Nuveen's aTyr Pharma position peaked at $984K in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.